Sialyl Lewis a

General | Antibody | Glycoprotein | Glycolipid | Enzyme | Reference

Epitope information of EP0008

Epitope IDEP0008
Epitope nameSialyl Lewis a
AliasesSialyl Lea ,carbohydrate antigen 19-9 / CA19-9
HistorySialyl Lea was characherized as a tumor marker.[9*]
The term Lewis refers to the family name of individuals suffering from a red blood cell incompatibility problem that helped lead to the discovery of this blood group.
Molecular weight820.8

Homo sapiens

Tissue and Cellular distribution

Subcellular distribution

Developmental change

In normal tissues,Sialyl Lea antigen is expressed in biliary and pancreatic duct epithelia.[4]
Sialyl Lea is expressed in many malignant cells.[5]

Cell line

B16/mouse melanoma
BxPC-3/human pancreatic carcinoma
COLO 205/human colon adenocarcinoma
HL-60/human promyelocytic leukemia
HT-29/human colon adenocarcinoma
HT-29LMM/metastatic parental




The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[3]


pancreatic adenocarcinoma
hepatocellular cancer
cholangiocellular cancer
gastric cancer
colorectal cancer[24]
ovarian cancer
lung cancer
breast cancer
uterine cancer

CA 19-9 is detected with highest levels in excretory ductal pancreatic adenocarcinoma, biliary, hepatocellular and cholangiocellular cancer besides gastric, colorectal and ovarian cancer and occasionally in lung, breast and uterine cancer.[2]

ApplicationThe monoclonal antibody NS 19-9 is a representative diagnostic agent for pancreatic adenocarcinoma and cholangiocellular cancer.

Mucins and BGM (bile globular membrane)(see Reference) are CA19-9 carriers in sera of patients with cancer.[25]